CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. (2018)
Attributed to:
MICA: Development of Metrics and Quality Standards for Scale up of Human Pluripotent Stem Cells
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/eurheartj/ehy249
PubMed Identifier: 29741611
Publication URI: http://europepmc.org/abstract/MED/29741611
Type: Journal Article/Review
Volume: 39
Parent Publication: European heart journal
Issue: 43
ISSN: 0195-668X